RegulatoryCompany release

Aptevo: 10 of 47 frontline AML patients on mipletamig triplet proceeded to transplant

🇺🇸 Aptevo Therapeutics Inc. (APVO) · Mon 26 Oct 2026

Aptevo says 10 of 47 evaluable newly diagnosed AML patients, initially unfit for intensive chemotherapy, reached allogeneic stem cell transplant after mipletamig plus venetoclax and azacitidine.

Aptevo Therapeutics reported on 26 October 2026 that 10 of 47 evaluable patients with newly diagnosed acute myeloid leukaemia (AML) went on to allogeneic stem cell transplant after treatment with mipletamig combined with venetoclax and azacitidine. All of the patients had initially been considered unfit for intensive chemotherapy.

The company set this against a transplant rate of 0.7% in the VIALE-A trial, in which patients received venetoclax and azacitidine alone. Aptevo acknowledged that comparisons across different trials have limits, so the figures do not amount to a head-to-head result.

The data come from the Phase 1b RAINIER study, where dose-optimisation work is expected to finish by the end of 2026. Aptevo plans to hold discussions with the US Food and Drug Administration and to start a Phase 2 study in the first half of 2027.

What it means for your team

  • The transplant figures are a cross-trial comparison against VIALE-A and should be read as hypothesis-generating, not as comparative evidence.
  • Regulatory teams should watch for the outcome of the planned FDA discussions, expected alongside completion of RAINIER dose optimisation by the end of 2026.
  • Market-access teams tracking frontline AML should note the Phase 2 start planned for the first half of 2027, which implies pivotal evidence is still some way off.

Company's press release (SEC filing): Aptevo Therapeutics Inc. ↗

Article written by VigiEye from the official source (Aptevo Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →